Advancing Drug Design to Counteract Resistance in Lung Cancer Treatment

Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab

• David Gandara
• Miranda Gogishvili
• Ahmet Sezer
• Tamta Makharadze
• Mahmut Gümüş
• Eric Yan
• James Harnett
• Ruben G. W. Quek